德国勃林格殷格翰9月18日宣布与德国CureVac合作，购买并共同开发后者新型mRNA治疗性疫苗CV9202，主要针对的适应症为肺癌。
根据双方签订的协议，勃林格殷格翰将首批支付CureVac公司3500万欧元并在达成预期目标之后支付额外4.3亿欧元以获得该疫苗的全球研发和商业权。 勃林格殷格翰将会负责该疫苗用于晚期或EGFR变异非小细胞肺癌以及不可切除III期非小细胞肺癌的治疗。
2014年7月第一周，赛诺菲宣布公司将开发一种基于Curevac公司的RNActive技术的疫苗，这一协议将带给CureVac公司高达2亿5百万美元的里程碑研究经费以及销售提成。赛诺菲研发高管Nicolas Burdin表示CureVac公司的RNActive技术将为赛诺菲的疫苗研发提供更为广阔的平台。RNActive技术的一大优势在于基于此技术的疫苗可以在常温保存，且在意外冷冻条件下疫苗不会失活。这为在发展中国家推广疫苗免疫，帮助这些国家和地区低收入人群对抗疾病有极其重大的意义。 法国赛诺菲巴斯德制药公司与德国CureVac公司早在2011年就已经建立了广泛合作关系，现在双方决定在mRNA疫苗领域进一步强化这种合作伙伴关系。
Boehringer Ingelheim and CureVac, leader in mRNA (messenger ribonucleic acid)-based drug development, jointly announce an exclusive global license and development collaboration. The new collaboration focuses on CureVac's CV9202, a novel investigational therapeutic mRNA vaccine in early clinical development for the treatment of lung cancer.
Boehringer Ingelheim will start clinical investigation of CV9202 in at least two different lung cancer settings, in combination with afatinib in patients with advanced or metastatic epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer (NSCLC) and in combination with chemo-radiation therapy in patients with unresectable stage III NSCLC. CureVac receives EUR 35 million (approximately $45 million). Further, CureVac can achieve milestone payments of up to EUR 430 million (approximately $556 million) and royalties on sales.
This new agreement is part of Boehringer Ingelheim's long-term commitment to delivering tomorrow's cancer therapies through the discovery of novel treatment options with high therapeutic value for patients. The company's oncology portfolio includes afatinib, a once-daily kinase inhibitor that irreversibly binds and inhibits ErbB1, ErbB2 and ErbB4 receptors and is approved in a number of markets including the EU and US. In the US, afatinib is marketed as Gilotrif for th first-line treatment of common types of EGFR-mutation positive metastatic NSCLC (Del 19 or L858R). Boehringer Ingelheim's oncology pipeline covers a broad range of solid tumors and hematologic malignancies (blood cancer), including two investigational compounds in Phase III clinical development: nintedanib in NSCLC and colorectal cancer, and volasertib in acute myeloid leukemia. These compounds are not approved, and their safety and efficacy have not been established.
"At Boehringer Ingelheim we are proud of our commitment to help improve the treatment of cancers with a high medical need. In our collaboration with CureVac, we will investigate combining existing treatments with the approach of sustained activation of the immune system. With this we hope to be able to develop new treatments and further expand our broad pipeline in lung cancer," said Professor Klaus Dugi, chief medical officer, Boehringer Ingelheim.
CureVac's mRNA-based technology represents a potential novel approach in cancer treatment. For the first time mRNA could be optimized to mobilize the patient's own immune system to fight the tumor with a specific immune response elicited through the RNActive vaccine. Cancer immunotherapy has been chosen as the "Breakthrough of the year 2013" by SCIENCE magazine. CV9202 is a combination of mRNA molecules coding for six antigens overexpressed in lung cancer, designed to induce an immune response against the tumor. CV9202 and the preceding RNActive cancer vaccine CV9201 tested in initial clinical trials by CureVac demonstrated activity in generating immune responses against all anti-tumor antigens.
Ingmar Hoerr, co-founder and CEO of CureVac GmbH commented: "This collaboration is extremely relevant for CureVac because, as a biotech enterprise, we rely on collaboration with strong partners for the clinical development and commercialization of our compounds. Cancer immunotherapy represents one of the biggest innovations in cancer treatment of recent times and we are delighted to now be working with Boehringer Ingelheim. The out-licensing and clinical development of our promising therapeutic vaccine CV9202 represents the logical next step in developing this novel treatment for cancer patients, and the significant commitment from Boehringer Ingelheim underscores the relevance of the mRNA technology."
CureVac, a clinical stage biopharmaceutical company from Tubingen, Germany, is pioneering the field of mRNA-based technology platforms for medical purposes with which mRNA is specifically optimized and formulated.
Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, CT, is the largest U.S. subsidiary of Boehringer Ingelheim Corporation (Ridgefield, CT) and a member of the Boehringer Ingelheim group of companies.
| 欢迎光临 药群论坛 (http://www.yaoqun.net/) | Powered by Discuz! X3.2 |
